Colorectal Cancer Clinical Trials & Research at Providence Medical Group
Gastric
Colorectal
Pancreatic Cancer
Colorectal cancer is the third most common type of cancer in men and women
in the U.S. Most colorectal cancers are adenocarcinomas (cancers that
begin in cells that make and release mucus and other fluids). Colorectal
cancer often begins as a growth called a polyp, which may form on the
inner wall of the colon or rectum. Some polyps become cancer over time.
Finding and removing polyps can prevent colorectal cancer.
Providence Medical Group is currently enrolling patients for the following
colorectal cancer clinical trials:
Gastric
1st-2nd line HER2-, CPS<5
Study Coordinator: Camille
initially 1 prior Rx ok but later will be 1st line, predominantly adeno
so GEJ and distal esoph ok, >6mos from completing adj
Rx: Dato-DXd + 5FU or cape
Colorectal Cancer
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients
With Stage II-III Colorectal Cancer
Treatment agent: Duloxetine
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips //Melissa.Phillips2@stjoe.org// (707) 521-3833
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04137107?term=NCT04137107&draw=2&rank=1
Sponsor: Alliance for Clinical Trials in Oncology with National Cancer
Institute
A2211805: Randomized Placebo Controlled, Duloxetine to Prevent Oxaliplatin-Induced
Peripheral Neuropathy (a PCRC study)
Study Coordinator: Melissa Phillips //Melissa.Phillips2@stjoe.org// (707) 521-3833
Stage 2-3 CRC, planning adjuvant FOLFOX (3-6mos) or CAPOX (3mos), no prior
neurotoxic chemo or prexisting neuropathy
MOUTAINEER-03: Randomized Ph 3 Tucatinib + Trastuzumab and mFOLFOX6 versus
mFOLFOX6 given with or without either Cetuximab or Bevacizumab 1L HER2+ Met CRC
Study Coordinator: Teresa x1103
HER2+ RAS wt, 1:1 randomization